HWHui Wang

Hui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Danzhu Wu

    Clinical Medical College of Jining Medical University, Jining, Shandong Province, China

    1 shared publication
  • Jiandong Zhang

    Department of Radiation Oncology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China

    1 shared publication
  • Liyuan Yang

    Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Taian, Shandong, China

    1 shared publication
  • Peng Dong

    Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute, Taian, Shandong, China

    1 shared publication
  • Xinshuang Yu

    Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, Shandong Lung Cancer Institute National Key Laboratory of Advanced Drug Delivery and Release Systems Jinan Shandong China

    1 shared publication
  • Yajuan Lv

    Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China

    1 shared publication

Latest Publications

  • Open Access

    Neoadjuvant Immunotherapy Improves Treatment for Early Resectable Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis

    by Peng Dong, Yu Yan, Liyuan Yang, Danzhu Wu, Hui Wang, Yajuan Lv, Jiandong Zhang, Xinshuang Yu

    Objective. Immunotherapy has shown better efficacy and less toxicity than chemotherapy in the treatment of non-small-cell lung cancer (NSCLC) at advanced stage. This study evaluates the safety and efficacy of neoadjuvant immunotherapy for resectable NSCLC. Methods. Literature examination was performed by searching the PubMed, the Cochrane Library, and Embase for articles evaluating the efficacy and safety of neoadjuvant immunotherapy for resectable NSCLC. The 95 confidence interval (CI) and effect sizes (ES) were evaluated. Heterogeneity and subgroup analysis were performed. Meta-analysis was carried out using Stata BE17 software. Results. In total, 678 patients from eighteen studies were recruited in this meta-analysis. The pathological complete response (pCR) and major pathological response (MPR) were used to evaluate the efficacy of neoadjuvant immunotherapy. Significantly higher MPR values were observed in neoadjuvant immunotherapy (MPR:ES=0.44; 95 CI: 0.330.55; pCR:ES=0.22; 95 CI: 0.150.30) compared with neoadjuvant chemotherapy (MPRConclusion. Neoadjuvant immunotherapy is safe and effective for resectable NSCLC.